An MTHFR test result tells you which variants you carry in the gene that produces methylenetetrahydrofolate reductase, the enzyme responsible for converting folate into its active form in your body. The test checks two specific spots on the gene, known as C677T and A1298C, and reports whether you have zero, one, or two copies of each variant. Understanding what those letter-and-number combinations mean, and how much they actually matter, requires looking beyond the raw genotype to your blood markers, your health history, and what the medical evidence says about real-world risk.
The Two Variants Your Test Reports
Every MTHFR test examines the same two locations on the gene. The first, C677T, refers to a spot where the DNA letter C is sometimes replaced by T. The second, A1298C, refers to a spot where the letter A can be replaced by C. You inherit one copy from each parent, so for each location your result will be one of three possibilities: no variant copies (called “wild type” or normal), one variant copy (heterozygous), or two variant copies (homozygous). On your lab report, the C677T result might read CC (normal), CT (heterozygous), or TT (homozygous). For the A1298C position, results read AA (normal), AC (heterozygous), or CC (homozygous).
These variants are common. In many populations, roughly a third of people carry at least one copy of the 677T allele, though rates vary by ethnicity and geography. A study of a Bosnian population found the 677T allele frequency at about 33%, consistent with many global populations, while the 1298C allele was more prevalent at about 38%.1PubMed Central. The Frequency of the 677C>T and 1298A>C Polymorphisms in the Methylenetetrahydrofolate Reductase (MTHFR) Gene in the Population Research in the United States has found striking differences across ethnic groups: African Americans appear to carry these variants less frequently, while Hispanic and Caucasian populations tend to have higher rates of C677T and A1298C, respectively.2PubMed Central. Ethnogeographic prevalence and implications of the 677C>T and 1298A>C MTHFR polymorphisms in US primary care populations Similar geographic gradients have been documented within China.3PubMed. Geographical and ethnic distribution of MTHFR gene polymorphisms and their associations with diseases among Chinese population The point here is that carrying one or both variants puts you in very large company, not in a rare-disease category.
How Each Genotype Affects Enzyme Activity
The reason these variants matter at all is that they change how well the MTHFR enzyme works. MTHFR converts folate from food and supplements into 5-methyltetrahydrofolate, the form your cells actually use for critical processes like DNA methylation and recycling homocysteine (an amino acid linked to cardiovascular risk when it accumulates).4PubMed Central. Folate Insufficiency Due to MTHFR Deficiency Is Bypassed by 5-Methyltetrahydrofolate Variants at these two gene locations produce an enzyme that is somewhat less efficient.
The C677T variant has the more dramatic effect. If you are homozygous TT, your enzyme retains only about 60% of normal activity. If you are heterozygous CT, the reduction is milder, around 65–70% of normal. The A1298C variant on its own has a smaller impact on enzyme function.5PubMed. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity A result of CC at position 677 and AA at position 1298 means your MTHFR enzyme works at full capacity. A single heterozygous result at either location is generally considered low-risk on its own, because the enzyme still functions well enough to keep folate metabolism running smoothly in most circumstances.
Compound Heterozygosity and Why It Gets Complicated
Where interpretation gets trickier is when you carry one variant copy at each location, a situation called compound heterozygosity (CT at 677 and AC at 1298). This combination shows up in a small but meaningful fraction of the population. Research estimates that about 2–3% of the general population carries compound heterozygous mutations, while about 8–9% may be homozygous at one of the two locations.6Ewha Medical Journal. Compound heterozygosity with methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C mutations likely causing recurrent thrombotic events in a middle-aged man: a case report
People who are compound heterozygous tend to have enzyme activity in the range of 50–60% of normal, which can produce a biochemical profile resembling that of 677TT homozygotes, including lower plasma folate and higher homocysteine.7PubMed Central. The combined effect of MTHFR C677T and A1298C polymorphisms on the risk of digestive system cancer among a hypertensive population However, the clinical picture is far from settled. One study looking at fasting homocysteine in compound heterozygotes found that the differences did not reach statistical significance, with only rare individual cases showing clearly elevated levels.8Clinical Chemistry. C677T and A1298C Polymorphisms of the Methylenetetrahydrofolate Reductase Gene: Incidence and Effect of Combined Genotypes on Plasma Fasting and Post-Methionine Load Homocysteine in Vascular Disease The takeaway: compound heterozygosity is worth noting, but the genotype alone does not predict whether your homocysteine or folate levels will actually be abnormal.
Reading Your Results Alongside Homocysteine and Folate
This is the single most important thing to understand about MTHFR results: the genotype by itself does not tell you whether anything is actually going wrong in your body. The genotype tells you about potential. Whether that potential translates into a problem depends on your diet, your folate intake, and how your homocysteine levels look in a blood test.
Homocysteine is the downstream marker that matters most. When MTHFR works poorly and folate is low, homocysteine accumulates because the recycling process stalls. Among people with the TT genotype and low folate, homocysteine levels have been shown to run about 24% higher than in those with normal genotypes.9PubMed. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations But when folate levels are adequate, this gap can narrow substantially or disappear. One study of vascular disease patients found no significant difference in homocysteine across genotype groups, though the TT group’s homocysteine levels were more sensitive to changes in folate. In other words, people with the TT genotype have less margin for error when dietary folate runs low.10PubMed. Common mutation in methylenetetrahydrofolate reductase. Correlation with homocysteine metabolism and late-onset vascular disease
If your MTHFR test shows a homozygous or compound heterozygous result, the practical next step is checking your serum homocysteine and folate levels. If homocysteine is in the normal range and folate status is adequate, the MTHFR variant is largely academic. If homocysteine is elevated, that is the actionable finding, regardless of what your genotype says.
What Professional Guidelines Actually Say
Here is where many people who receive MTHFR results run into a disconnect. The American College of Medical Genetics and Genomics (ACMG) published a practice guideline concluding that there is minimal clinical utility in MTHFR polymorphism testing and that it should not be ordered as part of a routine thrombophilia evaluation.11PubMed. ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing This is not because the variants are meaningless in every context. It is because, for most of the conditions people worry about (blood clots, heart disease, pregnancy loss), measuring and treating homocysteine directly is more informative and actionable than knowing the genotype behind it.
That guidance often clashes with what people encounter in direct-to-consumer genetic reports, integrative medicine clinics, and online health communities, where MTHFR status is sometimes treated as a diagnosis in itself. Genetic counseling literature has specifically flagged this as a dilemma: the two common MTHFR variants have been studied in connection with cardiovascular disease, recurrent pregnancy loss, neural tube defects, cancer, and neurodevelopmental disorders, but the evidence for using the genotype to direct treatment remains weak for most of those associations.12PubMed Central. MTHFR: Addressing Genetic Counseling Dilemmas Using Evidence-Based Literature
Reproductive Health and Neural Tube Defects
Reproductive concerns are among the most common reasons people look up their MTHFR results. The 677TT genotype was identified early on as a risk factor for neural tube defects like spina bifida.13PubMed Central. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? The mechanism makes biological sense: if the enzyme that activates folate is sluggish, a developing fetus may not get enough of the nutrient most critical for closing the neural tube. Research suggests this risk is compounded when both mother and fetus carry the TT genotype, because the mother’s reduced folate delivery adds to the fetus’s own impaired metabolism.14Genetics in Medicine. Spina bifida and folate-related genes: A study of gene-gene interactions
Both the C677T and A1298C variants have also been linked to unexplained recurrent pregnancy loss, and some researchers have recommended tailored management approaches for affected individuals, including low-dose aspirin and anticoagulants.15International Journal of Reproduction, Contraception, Obstetrics and Gynecology. Association of methylene tetrahydrofolate reductase gene mutation in unexplained recurrent pregnancy loss However, the broader obstetric community has not adopted MTHFR-based protocols as standard care. The universal recommendation for adequate folate supplementation before and during pregnancy applies regardless of genotype, and it largely addresses the mechanism by which MTHFR variants would cause harm. For anyone planning a pregnancy with a TT or compound heterozygous result, the most actionable step remains ensuring robust folate status, which a simple blood test can confirm.
The Link to Depression and Other Mental Health Conditions
One of the more intriguing findings in the MTHFR literature involves mental health. A large meta-analysis pooling over 1,200 depression cases and more than 10,000 controls found that people with the TT genotype at 677 had about a 36% higher odds of unipolar depression compared to those with the normal CC genotype, with the same analysis finding associations with schizophrenia and bipolar disorder.16American Journal of Epidemiology. Methylenetetrahydrofolate Reductase (MTHFR) Genetic Polymorphisms and Psychiatric Disorders: A HuGE Review A separate population-based study from Norway found that the TT genotype was linked to about 69% higher odds of depression without comorbid anxiety, and that elevated homocysteine nearly doubled the odds of that same diagnosis.17JAMA Psychiatry. Folate, Vitamin B12, Homocysteine, and the MTHFR 677C→T Polymorphism in Anxiety and Depression: The Hordaland Homocysteine Study
These associations have led some practitioners to recommend folate supplementation as an adjunct for patients with depression who carry the TT genotype. The logic is plausible, since folate is needed to produce S-adenosylmethionine, a molecule involved in neurotransmitter synthesis. But a 36% increase in odds is a modest effect size in the context of a complex disease like depression, and the variants explain only a small fraction of who gets depressed. A TT result on your MTHFR test does not mean you are destined for depression. It means you have one of many small genetic nudges that collectively shape risk.
Supplementation Strategies
If your MTHFR results show a variant and your homocysteine is elevated or your folate is low, supplementation is the standard response. The question that generates the most debate is whether to use regular folic acid or the pre-activated form called L-5-methyltetrahydrofolate (often marketed as methylfolate or 5-MTHF).
The reasoning behind methylfolate is straightforward: since the MTHFR enzyme’s job is to convert folate into 5-methyltetrahydrofolate, people whose enzyme works poorly might benefit from taking the end product directly, skipping the conversion step. Studies comparing the two forms at equivalent doses have found comparable bioavailability and similar effects on blood folate levels and homocysteine reduction.18PubMed. Folic acid and L-5-methyltetrahydrofolate: comparison of clinical pharmacokinetics and pharmacodynamics One advantage of 5-MTHF is that it does not require activation by the liver, making it immediately available and preventing the accumulation of unmetabolized folic acid that can occur when hepatic conversion capacity is overwhelmed.19PubMed. Folic acid versus 5- methyl tetrahydrofolate supplementation in pregnancy
A less well-known but important player is riboflavin, or vitamin B2. Riboflavin is the precursor for FAD, the molecule that the MTHFR enzyme uses as a cofactor to do its work. The C677T variant produces an enzyme that loses its grip on FAD more easily, so improving riboflavin status can partially stabilize the enzyme. In one trial, people homozygous for the TT genotype who took riboflavin supplements saw their homocysteine drop by about 22% overall. Among those who started with poor riboflavin status, the drop was as steep as 40%. No homocysteine response was seen in the CC or CT groups, making this a genotype-specific intervention.20PubMed. Riboflavin lowers homocysteine in individuals homozygous for the MTHFR 677C->T polymorphism Additional research has found that folate and riboflavin work together to lower homocysteine, possibly by maximizing the catalytic activity of MTHFR.21PubMed. Effect of riboflavin status on the homocysteine-lowering effect of folate in relation to the MTHFR (C677T) genotype
If you have the TT genotype and elevated homocysteine, a supplement strategy combining adequate folate (whether as methylfolate or folic acid) with riboflavin has the strongest evidence base. For people with CT or single-heterozygous results and normal homocysteine, aggressive supplementation is hard to justify beyond a standard multivitamin.
MTHFR and Drug Metabolism
One genuinely clinical context where MTHFR genotyping can matter is pharmacogenomics, specifically how your body handles certain medications. Methotrexate, used widely for autoimmune disease and cancer treatment, works by inhibiting folate metabolism. People with MTHFR variants who already have reduced folate processing can experience amplified toxicity from methotrexate. A study of patients with blood cancers receiving high-dose methotrexate found significantly different rates of blood cell, liver, kidney, and gastrointestinal toxicities across MTHFR genotypes. For example, the TT genotype at position 677 was associated with higher rates of severe gastrointestinal side effects compared to the CC genotype.22Scientific Reports. MTHFR and ABCB1 polymorphisms associated with toxicity in hematological malignancies patients receiving high dose methotrexate
This is one area where knowing your MTHFR status could plausibly change a clinical decision, particularly around dose adjustments or supportive care with leucovorin (a folate rescue agent). If you take or are about to start methotrexate, MTHFR results may be worth discussing with your prescribing physician even though mainstream guidelines do not recommend routine testing for other indications.
Pitfalls of Direct-to-Consumer Testing
Many people first learn about MTHFR variants through consumer genetic testing services rather than a physician-ordered lab. Raw data from these services gets uploaded to third-party interpretation tools that flag MTHFR status alongside dozens of other variants. Research has found that consumers face real challenges understanding these results and often seek out clinical help to interpret them.23PubMed Central. Consumer use and response to online third-party raw DNA interpretation services
A deeper issue is that the reports these tools generate can overstate the practical significance of common genetic variants. Researchers have demonstrated, using synthetic datasets built from published population data, that the likelihood of any single common variant like MTHFR C677T resulting in a meaningfully different health outcome for a specific individual is relatively small.24F1000Research. Using synthetic datasets to bridge the gap between the promise and reality of basing health-related decisions on common single nucleotide polymorphisms The variant is common precisely because it does not cause severe disease on its own. Evolution does not maintain a gene variant at 30–40% frequency in many populations if it is reliably harmful. What it does is create a slightly narrower margin for folate metabolism, which only becomes a problem under specific environmental conditions like poor diet, pregnancy, or certain medications.
The Epigenetic Dimension
One reason MTHFR results generate so much interest in functional medicine circles is the enzyme’s role in DNA methylation, a process that controls gene expression without changing DNA sequence. MTHFR produces the folate form needed to generate S-adenosylmethionine (SAM), the body’s primary methyl donor. When MTHFR activity is impaired, SAM production can drop, which in theory makes it harder for cells to keep genes properly methylated.
Research into autoimmune diseases illustrates this connection. In rheumatoid arthritis, patients who have not yet been treated show reduced methylation in T cells and joint tissue, and MTHFR variants that constrain SAM supply can aggravate that pattern. A similar dynamic appears in lupus, where certain immune cells exhibit widespread loss of normal methylation in association with impaired MTHFR activity.25PubMed Central. MTHFR‑folate axis as a modulator of the epigenetic landscape in autoimmune diseases The research here is still building, and it would be premature to draw treatment conclusions from it. But it helps explain why MTHFR status is plausible as a contributor to a wide range of conditions. Methylation is not some niche process; it is a core regulatory mechanism in every cell.
Can Too Much Folic Acid Backfire?
An unexpected wrinkle in the MTHFR story is the possibility that very high folic acid intake could paradoxically mimic the effects of an MTHFR deficiency. Animal research has shown that high folic acid intake actually reduced MTHFR protein levels and enzyme activity, lowered the production of 5-methyltetrahydrofolate, and decreased the SAM-to-SAH ratio, all changes that look biochemically similar to having a compromised MTHFR gene.26The American Journal of Clinical Nutrition. High folic acid consumption leads to pseudo-MTHFR deficiency, altered lipid metabolism, and liver injury in mice The researchers described this as a “pseudo-MTHFR deficiency.”
This finding is from a mouse model and the doses involved were well above typical human supplementation, so it should not cause alarm about taking a standard prenatal vitamin. But it does add nuance to the assumption that more folic acid is always better, particularly for people who already carry MTHFR variants. It is another argument for checking blood levels rather than simply escalating doses: for someone with a 677TT genotype who is already taking high-dose folic acid and still has elevated homocysteine, switching to methylfolate or adding riboflavin may be more productive than increasing the folic acid dose further.
Thrombosis, Cardiovascular Disease, and Realistic Risk
Blood clot risk and heart disease are probably the most anxiety-inducing associations people encounter after getting MTHFR results. The evidence here is real but often overstated. The compound heterozygous genotype has been linked to recurrent thrombotic events in case reports, but the same research notes that compound heterozygosity alone, without other clotting risk factors, has not been conclusively associated with high thrombotic risk.6Ewha Medical Journal. Compound heterozygosity with methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C mutations likely causing recurrent thrombotic events in a middle-aged man: a case report Additional risk factors like oral contraceptive use, pregnancy, immobility, or other inherited clotting disorders seem to be what tips the balance.
Large-scale data on cardiovascular disease shows that MTHFR variants are common among patients with arterial conditions, but so are they among people without those conditions. Homocysteine levels do track with both MTHFR genotype and hypertension, with T allele carriers who have high blood pressure showing higher homocysteine than C allele carriers with the same blood pressure status.27PubMed Central. Homocysteine levels, H-Hypertension, and the MTHFR C677T genotypes: A complex interaction But the ACMG’s stance remains that measuring and managing homocysteine directly is more useful than interpreting cardiovascular risk from an MTHFR genotype. Your doctor can check homocysteine with an inexpensive blood draw. If it is normal, the MTHFR result changes nothing about your cardiovascular management. If it is high, the interventions (folate, B vitamins, riboflavin, dietary changes) are the same whether or not you know your genotype.